Review



negative selection kit  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Miltenyi Biotec negative selection kit
    Negative Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 2269 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/NK+Cell+Isolation+Kit%2C+human/pm42013130-259-8-11
    Average 97 stars, based on 2269 article reviews
    negative selection kit - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Isolation:

    Article Title: IL-27 shapes NK cell heterogeneity and function in colorectal cancer.
    Article Snippet: For interferon (IFN)-γ production, splenic NK cells and tumor immune infiltrate derived from mice administered with an anti- IL- 27 antibody or with an isotype control antibody were cultured for 6 hours in the presence of the phorbol 12- myristate 13- acetate/ionomycin- based cell stimulation cocktail (1:500) (eBioscience, cat#004970- 93) and Brefeldin A (Sigma Aldrich, cat#B7651). .. Healthy donors’ peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep (Nycomed) gradient centrifugation as previously described.38 NK cells were negatively selected from PBMCs using the MACS human NK cell isolation kit (Miltenyi Biotec). ..

    Article Title: TBL1XR1 mutations promoted tumor progression in diffuse large B-cell lymphoma through impairing nature killer cytotoxicity via the MYC-CD47/PD-L1 axis.
    Article Snippet: .. Primary human NK cells, isolated from PBMCs of healthy donors using an NK cell isolation kit (130-092-657, Miltenyi Biotec, San Diego, CA), were used as effector cells. ..

    Article Title: SPP1-positive macrophages drive trastuzumab resistance in HER2-positive breast cancer.
    Article Snippet: The PBMC pellet from the buffy coat was collected and treated with red blood cell lysis buffer (Thermo Fisher, Cat# 00-4333-57) for 2 minutes to remove the red blood cells. .. Human NK cells were isolated using a Human NK Cell Isolation Ki (Miltenyi Biotec, Cat# 130-092-657) and according to the manufacturer’s instructions. .. Naive CD8+ T-cell Isolation Kit (Miltenyi Biotec, Cat# 130-093-244) was used to isolate naive CD8+ T cells according to the manufacturer’s instructions.

    Article Title: Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity
    Article Snippet: .. In brief, human NK cells were isolated 232 from human PBMCs by MACS (NK cell isola on kit, Miltenyi Cat# 130-092-657). .. 1x105 NK cells were 233 added per well in NK medium (RPMI + Glutamax (Invitrogen Cat# 61870-610), 10% HI FBS (Invitrogen 234 Cat# 26140-079), 2 mM L-glutamine (Gibco Cat# A2916801), 50 μM 2-mercaptoethanol (Gibco Cat# 235 31350-010), 100 μg/ml Penicillin/Streptomycin (Gibco Cat# 15070-063)) and cultured with 20 ng/ml 236 rhIL-2 (R&D Systems Cat# 202-IL) and 20 ng/ml rhIL-12 (R&D Systems Cat# 219-IL) together with 10 237 g/ml -TNFR2 mAb, 10 g/ml ctrl IgG or 100 ng/ml (or indicated concentra on of) rhTNF- (R&D 238 Systems Cat# 210-TA).

    Gradient Centrifugation:

    Article Title: IL-27 shapes NK cell heterogeneity and function in colorectal cancer.
    Article Snippet: For interferon (IFN)-γ production, splenic NK cells and tumor immune infiltrate derived from mice administered with an anti- IL- 27 antibody or with an isotype control antibody were cultured for 6 hours in the presence of the phorbol 12- myristate 13- acetate/ionomycin- based cell stimulation cocktail (1:500) (eBioscience, cat#004970- 93) and Brefeldin A (Sigma Aldrich, cat#B7651). .. Healthy donors’ peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep (Nycomed) gradient centrifugation as previously described.38 NK cells were negatively selected from PBMCs using the MACS human NK cell isolation kit (Miltenyi Biotec). ..

    Magnetic Cell Separation:

    Article Title: IL-27 shapes NK cell heterogeneity and function in colorectal cancer.
    Article Snippet: For interferon (IFN)-γ production, splenic NK cells and tumor immune infiltrate derived from mice administered with an anti- IL- 27 antibody or with an isotype control antibody were cultured for 6 hours in the presence of the phorbol 12- myristate 13- acetate/ionomycin- based cell stimulation cocktail (1:500) (eBioscience, cat#004970- 93) and Brefeldin A (Sigma Aldrich, cat#B7651). .. Healthy donors’ peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep (Nycomed) gradient centrifugation as previously described.38 NK cells were negatively selected from PBMCs using the MACS human NK cell isolation kit (Miltenyi Biotec). ..

    Article Title: GBP6 maintains mitochondrial bioenergetics to promote immune evasion from NK cells in cervical cancer.
    Article Snippet: .. After two washes with PBS, the NK cells were negatively selected using the magnetic-activated cell Sorting Kit (MACS) NK Cell Isolation Kit (Miltenyi Biotec, 130-092-657) according to the manufacturer’s protocol. ..

    Article Title: Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity
    Article Snippet: .. In brief, human NK cells were isolated 232 from human PBMCs by MACS (NK cell isola on kit, Miltenyi Cat# 130-092-657). .. 1x105 NK cells were 233 added per well in NK medium (RPMI + Glutamax (Invitrogen Cat# 61870-610), 10% HI FBS (Invitrogen 234 Cat# 26140-079), 2 mM L-glutamine (Gibco Cat# A2916801), 50 μM 2-mercaptoethanol (Gibco Cat# 235 31350-010), 100 μg/ml Penicillin/Streptomycin (Gibco Cat# 15070-063)) and cultured with 20 ng/ml 236 rhIL-2 (R&D Systems Cat# 202-IL) and 20 ng/ml rhIL-12 (R&D Systems Cat# 219-IL) together with 10 237 g/ml -TNFR2 mAb, 10 g/ml ctrl IgG or 100 ng/ml (or indicated concentra on of) rhTNF- (R&D 238 Systems Cat# 210-TA).

    Cell Isolation:

    Article Title: IL-27 shapes NK cell heterogeneity and function in colorectal cancer.
    Article Snippet: For interferon (IFN)-γ production, splenic NK cells and tumor immune infiltrate derived from mice administered with an anti- IL- 27 antibody or with an isotype control antibody were cultured for 6 hours in the presence of the phorbol 12- myristate 13- acetate/ionomycin- based cell stimulation cocktail (1:500) (eBioscience, cat#004970- 93) and Brefeldin A (Sigma Aldrich, cat#B7651). .. Healthy donors’ peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep (Nycomed) gradient centrifugation as previously described.38 NK cells were negatively selected from PBMCs using the MACS human NK cell isolation kit (Miltenyi Biotec). ..

    Article Title: TBL1XR1 mutations promoted tumor progression in diffuse large B-cell lymphoma through impairing nature killer cytotoxicity via the MYC-CD47/PD-L1 axis.
    Article Snippet: .. Primary human NK cells, isolated from PBMCs of healthy donors using an NK cell isolation kit (130-092-657, Miltenyi Biotec, San Diego, CA), were used as effector cells. ..

    Article Title: GBP6 maintains mitochondrial bioenergetics to promote immune evasion from NK cells in cervical cancer.
    Article Snippet: .. After two washes with PBS, the NK cells were negatively selected using the magnetic-activated cell Sorting Kit (MACS) NK Cell Isolation Kit (Miltenyi Biotec, 130-092-657) according to the manufacturer’s protocol. ..

    Article Title: SPP1-positive macrophages drive trastuzumab resistance in HER2-positive breast cancer.
    Article Snippet: The PBMC pellet from the buffy coat was collected and treated with red blood cell lysis buffer (Thermo Fisher, Cat# 00-4333-57) for 2 minutes to remove the red blood cells. .. Human NK cells were isolated using a Human NK Cell Isolation Ki (Miltenyi Biotec, Cat# 130-092-657) and according to the manufacturer’s instructions. .. Naive CD8+ T-cell Isolation Kit (Miltenyi Biotec, Cat# 130-093-244) was used to isolate naive CD8+ T cells according to the manufacturer’s instructions.

    other:

    Article Title: Depletion of an immature cord blood NK subset reverses trogocytosis-driven CAR NK dysfunction.
    Article Snippet: Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J., Wilk, A.J., Darby, C., Zager, M., et al. (2021).

    FACS:

    Article Title: GBP6 maintains mitochondrial bioenergetics to promote immune evasion from NK cells in cervical cancer.
    Article Snippet: .. After two washes with PBS, the NK cells were negatively selected using the magnetic-activated cell Sorting Kit (MACS) NK Cell Isolation Kit (Miltenyi Biotec, 130-092-657) according to the manufacturer’s protocol. ..



    Similar Products

    94
    MedChemExpress immunomagnetic separation kit
    Immunomagnetic Separation Kit, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pmc13458028-145-14-25
    Average 94 stars, based on 1 article reviews
    immunomagnetic separation kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec pan t cell negative selection kit
    Pan T Cell Negative Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Pan+T+Cell+Isolation+Kit%2C+human/pmc13336833-111-10-16
    Average 97 stars, based on 1 article reviews
    pan t cell negative selection kit - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    94
    MedChemExpress human cd8 t cells
    Human Cd8 T Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pm42431878-333-13-28
    Average 94 stars, based on 1 article reviews
    human cd8 t cells - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec magnetic negative selection
    Magnetic Negative Selection, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Naive+CD4%2B+T+Cell+Isolation+Kit+II%2C+human/pmc13284711-33-11-21
    Average 96 stars, based on 1 article reviews
    magnetic negative selection - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec immunomagnetic negative selection
    Immunomagnetic Negative Selection, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/B+Cell+Isolation+Kit%2C+mouse/pm42247288-209-25-29
    Average 96 stars, based on 1 article reviews
    immunomagnetic negative selection - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec immunomagnetic negative selection kit
    Immunomagnetic Negative Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Pan+B+Cell+Isolation+Kit%2C+mouse/pm42230556-305-13-24
    Average 95 stars, based on 1 article reviews
    immunomagnetic negative selection kit - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress human cd8 t cell negative selection
    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also  and  .
    Human Cd8 T Cell Negative Selection, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pmc13130659-81-0-8
    Average 94 stars, based on 1 article reviews
    human cd8 t cell negative selection - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec negative selection kit
    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also  and  .
    Negative Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/NK+Cell+Isolation+Kit%2C+human/pm42013130-259-8-11
    Average 97 stars, based on 1 article reviews
    negative selection kit - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    94
    MedChemExpress human cd8 t cell negative selection kit
    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), <t>CD8</t> (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .
    Human Cd8 T Cell Negative Selection Kit, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/Human+CD8%2B+T+Cells+Negative+Selection+Kit/pmc13130659-446-11-19
    Average 94 stars, based on 1 article reviews
    human cd8 t cell negative selection kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec negative selection macs separation kit
    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), <t>CD8</t> (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .
    Negative Selection Macs Separation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+selection+kit/B+Cell+Isolation+Kit+II%2C+human/pmc13130636-396-6-11
    Average 96 stars, based on 1 article reviews
    negative selection macs separation kit - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also  and  .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .

    Article Snippet: Human CD8 + T cell Negative Selection , MedChemExpress , Cat#HY-KO351.

    Techniques: Western Blot, Expressing, Control, Immunostaining, TUNEL Assay, Enzyme-linked Immunosorbent Assay

    mBH3@NPs promoted the recruitment of adoptively transferred T cells (A) Schematic of transwell migration assay using B16-OVA cells and preactivated OT-1 T cells. (B) Transwell migration assay of OT-I T cells (CFDA-labeled). Representative flow cytometry graphs and quantification of T cell infiltration relative fold changes (calculated as the ratio of bottom well-located OT-I T cells to counting beads) ( n = 3). (C) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells in B16-OVA tumor-bearing mice. (D) Serial IVIS images and quantification of infiltrating Cy5-T cell signals in B16-OVA tumor-bearing mice ( n = 5). (E) Quantification of tumor-infiltrating endogenous T cells and transferred CD8 + T cells per million cells ( n = 5). (F) Heatmap of RNA-seq data for key interleukin family member, chemokine family member, and granzyme family member from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (G) Heatmap of the differences in pathway activities scored by GSVA from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (H) Validation of key cytokines and chemokines expression by multiplex cytokine assay. Tumor tissue was homogenized, and the cell supernatant of each treatment group was collected ( n = 4). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also  .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs promoted the recruitment of adoptively transferred T cells (A) Schematic of transwell migration assay using B16-OVA cells and preactivated OT-1 T cells. (B) Transwell migration assay of OT-I T cells (CFDA-labeled). Representative flow cytometry graphs and quantification of T cell infiltration relative fold changes (calculated as the ratio of bottom well-located OT-I T cells to counting beads) ( n = 3). (C) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells in B16-OVA tumor-bearing mice. (D) Serial IVIS images and quantification of infiltrating Cy5-T cell signals in B16-OVA tumor-bearing mice ( n = 5). (E) Quantification of tumor-infiltrating endogenous T cells and transferred CD8 + T cells per million cells ( n = 5). (F) Heatmap of RNA-seq data for key interleukin family member, chemokine family member, and granzyme family member from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (G) Heatmap of the differences in pathway activities scored by GSVA from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (H) Validation of key cytokines and chemokines expression by multiplex cytokine assay. Tumor tissue was homogenized, and the cell supernatant of each treatment group was collected ( n = 4). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Article Snippet: Human CD8 + T cell Negative Selection , MedChemExpress , Cat#HY-KO351.

    Techniques: Transwell Migration Assay, Labeling, Flow Cytometry, RNA Sequencing, Gene Expression, Biomarker Discovery, Expressing, Multiplex Assay, Cytokine Assay

    mBH3@NPs combined with adoptive T cell therapy improved the therapeutic effect (A) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells from PMEL mice in B16-F10-tumor-bearing mice. (B) The average tumor volume curves for mice treated in the B16-F10-tumor-bearing mice model ( n = 7). (C) Survival analysis for mice treated in B16-F10-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). The x axis indicates days post-mBH3@NPs administration. (D) Experimental timeline for mBH3@NPs administration combined with adoptive transfered T cells from OT-1 mice in B16-OVA-tumor-bearing mice. (E) The average tumor volume curves for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). (F) Survival analysis for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). (G) Representative flow cytometry plot and quantification of CD44 and CD62L expression levels gated on total CD8 + T cells (upper panel) and the percentage of endogenous (CD90.2) CD8 + T cells and transferred PMEL (CD90.1) CD8 + T cells gated on total CD8 + T cells (lower panel) ( n = 5). (H) Representative flow cytometry plot and quantification of the expression level of granzyme B (GrB) and perforin in total CD8 + T cells from tumors and spleens ( n = 5). (I) Representative flow cytometry plot and quantification of the expression level of PD-1 and LAG-3 in both endogenous and transferred PMEL CD8 + T cells from tumors ( n = 5). (J) Immunofluorescence evaluation of CD8 + T cell exhaustion, effector, and memory function. Upper panel: representative immunofluorescence images of tumors from different groups for analyzing the exhaustion (PD-1 + , cyan) and effector function (IFN-γ + , green) of CD8 + T cells (CD8 + , pink). Scale bars, 100 μm. Lower panel: representative immunofluorescence images of tumor-infiltrating CD8 + T cells (CD8 + , green) along with markers for activation (CD69 + , red) and memory differentiation (CD44 + , pink; CCR7 + , cyan). Scale bars, 200 μm ( n = 3). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also  .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs combined with adoptive T cell therapy improved the therapeutic effect (A) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells from PMEL mice in B16-F10-tumor-bearing mice. (B) The average tumor volume curves for mice treated in the B16-F10-tumor-bearing mice model ( n = 7). (C) Survival analysis for mice treated in B16-F10-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). The x axis indicates days post-mBH3@NPs administration. (D) Experimental timeline for mBH3@NPs administration combined with adoptive transfered T cells from OT-1 mice in B16-OVA-tumor-bearing mice. (E) The average tumor volume curves for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). (F) Survival analysis for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). (G) Representative flow cytometry plot and quantification of CD44 and CD62L expression levels gated on total CD8 + T cells (upper panel) and the percentage of endogenous (CD90.2) CD8 + T cells and transferred PMEL (CD90.1) CD8 + T cells gated on total CD8 + T cells (lower panel) ( n = 5). (H) Representative flow cytometry plot and quantification of the expression level of granzyme B (GrB) and perforin in total CD8 + T cells from tumors and spleens ( n = 5). (I) Representative flow cytometry plot and quantification of the expression level of PD-1 and LAG-3 in both endogenous and transferred PMEL CD8 + T cells from tumors ( n = 5). (J) Immunofluorescence evaluation of CD8 + T cell exhaustion, effector, and memory function. Upper panel: representative immunofluorescence images of tumors from different groups for analyzing the exhaustion (PD-1 + , cyan) and effector function (IFN-γ + , green) of CD8 + T cells (CD8 + , pink). Scale bars, 100 μm. Lower panel: representative immunofluorescence images of tumor-infiltrating CD8 + T cells (CD8 + , green) along with markers for activation (CD69 + , red) and memory differentiation (CD44 + , pink; CCR7 + , cyan). Scale bars, 200 μm ( n = 3). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Article Snippet: Human CD8 + T cell Negative Selection , MedChemExpress , Cat#HY-KO351.

    Techniques: Flow Cytometry, Expressing, Immunofluorescence, Activation Assay

    Combination therapy drove CD8 + T cells toward memory-like states with expanded TCR diversity (A) Experimental design for scRNA-seq. Mice were treated with ACT alone or combined with mBim@NPs and mPuma@NPs as shown ( n = 3); CD3 + T cell isolated from mice for scRNA-seq. (B) UMAP representation and distribution of 68,176 cells of the CD8 + T cell atlas in each experimental condition, colored by 12 CD8 + T cell subtypes annotated in this study. (C) UMAP representation of the CD8 + T cells atlas colored by each experimental condition. (D) A dot plot showing the expression levels of marker genes in each CD8 + T cell subtype. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (E) Indicated expression of gene marker associated with memory ( Tcf7 , Il7r , Sell , and Ccl5 ), exhaustion ( Pdcd1 , Tigit , and Lag3 ), and cytotoxicity ( Gzmb , Ifng , and Prf1 ) in the UMAP plot. (F) A dot plot showing the expression levels of marker genes in  E. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype.  (G) Volcano plots of log 2 (fold change) and log 10 (adjusted FDR value) of differentially expressed genes in proliferating T and Gzmk + T rm from mice treated with ACT monotherapy and combination therapy with mBim@NPs. (H) Shannon entropy of the T ex , proliferating T, T naive , and Gzmk + T rm subsets across different treatment groups (T: ACT monotherapy; TP: ACT + mPuma@NPs; TB: ACT + mBim@NPs). (I) Shannon entropy of total CD8 + T cells and CD4 + T cells across different treatment groups. (J) A heatmap of normalized Shannon entropy for CD8 + T cell subsets across different treatment groups. See also  .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: Combination therapy drove CD8 + T cells toward memory-like states with expanded TCR diversity (A) Experimental design for scRNA-seq. Mice were treated with ACT alone or combined with mBim@NPs and mPuma@NPs as shown ( n = 3); CD3 + T cell isolated from mice for scRNA-seq. (B) UMAP representation and distribution of 68,176 cells of the CD8 + T cell atlas in each experimental condition, colored by 12 CD8 + T cell subtypes annotated in this study. (C) UMAP representation of the CD8 + T cells atlas colored by each experimental condition. (D) A dot plot showing the expression levels of marker genes in each CD8 + T cell subtype. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (E) Indicated expression of gene marker associated with memory ( Tcf7 , Il7r , Sell , and Ccl5 ), exhaustion ( Pdcd1 , Tigit , and Lag3 ), and cytotoxicity ( Gzmb , Ifng , and Prf1 ) in the UMAP plot. (F) A dot plot showing the expression levels of marker genes in E. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (G) Volcano plots of log 2 (fold change) and log 10 (adjusted FDR value) of differentially expressed genes in proliferating T and Gzmk + T rm from mice treated with ACT monotherapy and combination therapy with mBim@NPs. (H) Shannon entropy of the T ex , proliferating T, T naive , and Gzmk + T rm subsets across different treatment groups (T: ACT monotherapy; TP: ACT + mPuma@NPs; TB: ACT + mBim@NPs). (I) Shannon entropy of total CD8 + T cells and CD4 + T cells across different treatment groups. (J) A heatmap of normalized Shannon entropy for CD8 + T cell subsets across different treatment groups. See also .

    Article Snippet: Human CD8 + T cell Negative Selection , MedChemExpress , Cat#HY-KO351.

    Techniques: Isolation, Expressing, Marker

    mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs induced effective antitumor immunity and remodeled the tumor microenvironment (A) Experimental timeline for mBH3@NPs administration in B16-F10-tumor-bearing mice. Mice were administered with mBH3@NPs three times, with a dosing interval of every 2 days (B) Average tumor volume curves for mice treated in the melanoma model ( n = 8). (C) Individual tumor volume curves for mice treated in the melanoma model ( n = 8). (D) Western blot analysis of Bax, Bak, Bcl-2, Bcl-x L , Mcl-1, Puma, Bim, caspase-3, and caspase-9 expression following different treatments. β-Actin was used as a loading control ( n = 3). (E) Representative images of tumor immunostaining and quantification for TUNEL (green)/DAPI (blue), CD8 (red)/DAPI (blue), and CRT (green)/DAPI (blue) at day 19 following the indicated treatments in the melanoma model. Scale bars, 200 μm. (F) HMGB1 expression in tumor tissues analyzed by ELISA following different treatments ( n = 5). (G) Heatmap of cytokine expression levels (GrB, IFN-γ, TNF-α, IL-12, and IL-6) in tumor tissues following different treatments ( n = 5). (H) Flow cytometric analysis of immune cell populations (T cells, CD8 + T cells, CD4 + T cells, Treg cells, NK cells, macrophages, M1-like TAMs, M2-like TAMs, and MDSCs) within tumors and CD11c + CD80 + CD86 + mature dendritic cells in lymph nodes ( n = 5). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also and .

    Article Snippet: Human CD8 + T cells were isolated from PBMCs using the Human CD8 + T cell Negative Selection Kit (MedChemExpress, #HY-KO351).

    Techniques: Western Blot, Expressing, Control, Immunostaining, TUNEL Assay, Enzyme-linked Immunosorbent Assay

    mBH3@NPs promoted the recruitment of adoptively transferred T cells (A) Schematic of transwell migration assay using B16-OVA cells and preactivated OT-1 T cells. (B) Transwell migration assay of OT-I T cells (CFDA-labeled). Representative flow cytometry graphs and quantification of T cell infiltration relative fold changes (calculated as the ratio of bottom well-located OT-I T cells to counting beads) ( n = 3). (C) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells in B16-OVA tumor-bearing mice. (D) Serial IVIS images and quantification of infiltrating Cy5-T cell signals in B16-OVA tumor-bearing mice ( n = 5). (E) Quantification of tumor-infiltrating endogenous T cells and transferred CD8 + T cells per million cells ( n = 5). (F) Heatmap of RNA-seq data for key interleukin family member, chemokine family member, and granzyme family member from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (G) Heatmap of the differences in pathway activities scored by GSVA from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (H) Validation of key cytokines and chemokines expression by multiplex cytokine assay. Tumor tissue was homogenized, and the cell supernatant of each treatment group was collected ( n = 4). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs promoted the recruitment of adoptively transferred T cells (A) Schematic of transwell migration assay using B16-OVA cells and preactivated OT-1 T cells. (B) Transwell migration assay of OT-I T cells (CFDA-labeled). Representative flow cytometry graphs and quantification of T cell infiltration relative fold changes (calculated as the ratio of bottom well-located OT-I T cells to counting beads) ( n = 3). (C) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells in B16-OVA tumor-bearing mice. (D) Serial IVIS images and quantification of infiltrating Cy5-T cell signals in B16-OVA tumor-bearing mice ( n = 5). (E) Quantification of tumor-infiltrating endogenous T cells and transferred CD8 + T cells per million cells ( n = 5). (F) Heatmap of RNA-seq data for key interleukin family member, chemokine family member, and granzyme family member from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (G) Heatmap of the differences in pathway activities scored by GSVA from harvested tumor tissues, plotted as Z score of normalized gene expression for each gene ( n = 3). (H) Validation of key cytokines and chemokines expression by multiplex cytokine assay. Tumor tissue was homogenized, and the cell supernatant of each treatment group was collected ( n = 4). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Article Snippet: Human CD8 + T cells were isolated from PBMCs using the Human CD8 + T cell Negative Selection Kit (MedChemExpress, #HY-KO351).

    Techniques: Transwell Migration Assay, Labeling, Flow Cytometry, RNA Sequencing, Gene Expression, Biomarker Discovery, Expressing, Multiplex Assay, Cytokine Assay

    mBH3@NPs combined with adoptive T cell therapy improved the therapeutic effect (A) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells from PMEL mice in B16-F10-tumor-bearing mice. (B) The average tumor volume curves for mice treated in the B16-F10-tumor-bearing mice model ( n = 7). (C) Survival analysis for mice treated in B16-F10-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). The x axis indicates days post-mBH3@NPs administration. (D) Experimental timeline for mBH3@NPs administration combined with adoptive transfered T cells from OT-1 mice in B16-OVA-tumor-bearing mice. (E) The average tumor volume curves for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). (F) Survival analysis for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). (G) Representative flow cytometry plot and quantification of CD44 and CD62L expression levels gated on total CD8 + T cells (upper panel) and the percentage of endogenous (CD90.2) CD8 + T cells and transferred PMEL (CD90.1) CD8 + T cells gated on total CD8 + T cells (lower panel) ( n = 5). (H) Representative flow cytometry plot and quantification of the expression level of granzyme B (GrB) and perforin in total CD8 + T cells from tumors and spleens ( n = 5). (I) Representative flow cytometry plot and quantification of the expression level of PD-1 and LAG-3 in both endogenous and transferred PMEL CD8 + T cells from tumors ( n = 5). (J) Immunofluorescence evaluation of CD8 + T cell exhaustion, effector, and memory function. Upper panel: representative immunofluorescence images of tumors from different groups for analyzing the exhaustion (PD-1 + , cyan) and effector function (IFN-γ + , green) of CD8 + T cells (CD8 + , pink). Scale bars, 100 μm. Lower panel: representative immunofluorescence images of tumor-infiltrating CD8 + T cells (CD8 + , green) along with markers for activation (CD69 + , red) and memory differentiation (CD44 + , pink; CCR7 + , cyan). Scale bars, 200 μm ( n = 3). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: mBH3@NPs combined with adoptive T cell therapy improved the therapeutic effect (A) Experimental timeline for mBH3@NPs administration combined with adoptively transferred T cells from PMEL mice in B16-F10-tumor-bearing mice. (B) The average tumor volume curves for mice treated in the B16-F10-tumor-bearing mice model ( n = 7). (C) Survival analysis for mice treated in B16-F10-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). The x axis indicates days post-mBH3@NPs administration. (D) Experimental timeline for mBH3@NPs administration combined with adoptive transfered T cells from OT-1 mice in B16-OVA-tumor-bearing mice. (E) The average tumor volume curves for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). (F) Survival analysis for mice treated in B16-OVA-tumor-bearing mice model ( n = 7). Mice were humanely euthanized when tumor volume reached the predefined ethical endpoint (15 mm × 15 mm). (G) Representative flow cytometry plot and quantification of CD44 and CD62L expression levels gated on total CD8 + T cells (upper panel) and the percentage of endogenous (CD90.2) CD8 + T cells and transferred PMEL (CD90.1) CD8 + T cells gated on total CD8 + T cells (lower panel) ( n = 5). (H) Representative flow cytometry plot and quantification of the expression level of granzyme B (GrB) and perforin in total CD8 + T cells from tumors and spleens ( n = 5). (I) Representative flow cytometry plot and quantification of the expression level of PD-1 and LAG-3 in both endogenous and transferred PMEL CD8 + T cells from tumors ( n = 5). (J) Immunofluorescence evaluation of CD8 + T cell exhaustion, effector, and memory function. Upper panel: representative immunofluorescence images of tumors from different groups for analyzing the exhaustion (PD-1 + , cyan) and effector function (IFN-γ + , green) of CD8 + T cells (CD8 + , pink). Scale bars, 100 μm. Lower panel: representative immunofluorescence images of tumor-infiltrating CD8 + T cells (CD8 + , green) along with markers for activation (CD69 + , red) and memory differentiation (CD44 + , pink; CCR7 + , cyan). Scale bars, 200 μm ( n = 3). One-way ANOVA with Tukey’s multiple comparisons test was used for all statistical analyses. Data are presented as the mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; NS, not significant. See also .

    Article Snippet: Human CD8 + T cells were isolated from PBMCs using the Human CD8 + T cell Negative Selection Kit (MedChemExpress, #HY-KO351).

    Techniques: Flow Cytometry, Expressing, Immunofluorescence, Activation Assay

    Combination therapy drove CD8 + T cells toward memory-like states with expanded TCR diversity (A) Experimental design for scRNA-seq. Mice were treated with ACT alone or combined with mBim@NPs and mPuma@NPs as shown ( n = 3); CD3 + T cell isolated from mice for scRNA-seq. (B) UMAP representation and distribution of 68,176 cells of the CD8 + T cell atlas in each experimental condition, colored by 12 CD8 + T cell subtypes annotated in this study. (C) UMAP representation of the CD8 + T cells atlas colored by each experimental condition. (D) A dot plot showing the expression levels of marker genes in each CD8 + T cell subtype. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (E) Indicated expression of gene marker associated with memory ( Tcf7 , Il7r , Sell , and Ccl5 ), exhaustion ( Pdcd1 , Tigit , and Lag3 ), and cytotoxicity ( Gzmb , Ifng , and Prf1 ) in the UMAP plot. (F) A dot plot showing the expression levels of marker genes in E. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (G) Volcano plots of log 2 (fold change) and log 10 (adjusted FDR value) of differentially expressed genes in proliferating T and Gzmk + T rm from mice treated with ACT monotherapy and combination therapy with mBim@NPs. (H) Shannon entropy of the T ex , proliferating T, T naive , and Gzmk + T rm subsets across different treatment groups (T: ACT monotherapy; TP: ACT + mPuma@NPs; TB: ACT + mBim@NPs). (I) Shannon entropy of total CD8 + T cells and CD4 + T cells across different treatment groups. (J) A heatmap of normalized Shannon entropy for CD8 + T cell subsets across different treatment groups. See also .

    Journal: Cell Reports Medicine

    Article Title: mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy

    doi: 10.1016/j.xcrm.2026.102706

    Figure Lengend Snippet: Combination therapy drove CD8 + T cells toward memory-like states with expanded TCR diversity (A) Experimental design for scRNA-seq. Mice were treated with ACT alone or combined with mBim@NPs and mPuma@NPs as shown ( n = 3); CD3 + T cell isolated from mice for scRNA-seq. (B) UMAP representation and distribution of 68,176 cells of the CD8 + T cell atlas in each experimental condition, colored by 12 CD8 + T cell subtypes annotated in this study. (C) UMAP representation of the CD8 + T cells atlas colored by each experimental condition. (D) A dot plot showing the expression levels of marker genes in each CD8 + T cell subtype. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (E) Indicated expression of gene marker associated with memory ( Tcf7 , Il7r , Sell , and Ccl5 ), exhaustion ( Pdcd1 , Tigit , and Lag3 ), and cytotoxicity ( Gzmb , Ifng , and Prf1 ) in the UMAP plot. (F) A dot plot showing the expression levels of marker genes in E. The color of the dots indicates the average scaled expression level, and the size of the dots indicates the percentage of cells expressing the gene in each subtype. (G) Volcano plots of log 2 (fold change) and log 10 (adjusted FDR value) of differentially expressed genes in proliferating T and Gzmk + T rm from mice treated with ACT monotherapy and combination therapy with mBim@NPs. (H) Shannon entropy of the T ex , proliferating T, T naive , and Gzmk + T rm subsets across different treatment groups (T: ACT monotherapy; TP: ACT + mPuma@NPs; TB: ACT + mBim@NPs). (I) Shannon entropy of total CD8 + T cells and CD4 + T cells across different treatment groups. (J) A heatmap of normalized Shannon entropy for CD8 + T cell subsets across different treatment groups. See also .

    Article Snippet: Human CD8 + T cells were isolated from PBMCs using the Human CD8 + T cell Negative Selection Kit (MedChemExpress, #HY-KO351).

    Techniques: Isolation, Expressing, Marker